Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses.

Autor:	Nakashima Y; a Department of Orthopaedic Surgery , Kyushu University , Fukuoka , Japan., Miyahara H; b Department of Orthopedics , National Hospital Organization Kyushu Medical Center , Fukuoka , Japan., Kondo M; c Kondo Clinic of Rheumatology and Orthopaedic Surgery , Fukuoka , Japan., Fukuda T; d Center for Rheumatic Diseases, Kurume University Medical Center , Kurume , Japan., Harada H; e Morooka Orthopedic Clinic , Fukuoka , Japan., Haraguchi A; a Department of Orthopaedic Surgery , Kyushu University , Fukuoka , Japan., Inoue Y; f Department of rheumatology , Fukuoka Red Cross Hospital , Fukuoka , Japan., Ishinishi T; g Ishinishi Orthopaedic Clinic , Fukuoka , Japan., Maekawa M; h Maekawa Orthopedics , Yahata , Japan., Maeyama A; i Department of Orthopedic Surgery , Fukuoka University , Fukuoka , Japan., Nakashima M; d Center for Rheumatic Diseases, Kurume University Medical Center , Kurume , Japan., Shono E; j Shono Rheumatology Clinic , Fukuoka , Japan., Suematsu E; k Department of Internal Medicine and Rheumatology , National Hospital Organization Kyushu Medical Center , Fukuoka , Japan., Shimauchi T; l Fukuoka Hoeikai Hospital , Fukuoka , Japan., Tsuru T; m PS Clinic , Fukuoka , Japan., Tsukamoto H; n Department of Medicine and Biosystemic Science , Kyushu University , Fukuoka , Japan., Yoshizawa S; o National Fukuoka Hospital , Fukuoka , Japan , and., Yoshizawa S; p Hamanomachi Hospital , Fukuoka , Japan., Iwamoto Y; a Department of Orthopaedic Surgery , Kyushu University , Fukuoka , Japan.
Jazyk:	angličtina
Zdroj:	Modern rheumatology [Mod Rheumatol] 2017 Jan; Vol. 27 (1), pp. 15-21. Date of Electronic Publication: 2016 May 04.
DOI:	10.3109/14397595.2016.1170958
Abstrakt:	Objective: Upper limit of methotrexate (MTX) for patients with rheumatoid arthritis (RA) was recently increased from 8 to 16 mg/week in Japan. We therefore examined the effect of concomitant MTX dose on the efficacy of adalimumab (ADA) in clinical practice. Method: Sixty-one consecutive RA patients treated with ADA were followed for minimum 52 weeks and retrospectively compared by MTX dose; patients receiving concomitant MTX of 10 mg/week or more (MTX ≥10 mg group) and <10 mg/week (MTX <10 mg group). Disease activity and remission were evaluated by the disease activity score 28 (DAS28) criteria. Results: The MTX ≥10 mg group consistently showed better improvement in DAS28 and resulted in more patients (52.8%) with DAS28-remission compared with the MTX <10 mg group (26.1%). Multivariate analysis showed that MTX ≥10 mg had a significant effect on DAS28 remission with odds ratio of 5.12. ADA retention rate was 72.2% in MTX ≥10 mg group compared with 52.0% in MTX <10 mg group. Discontinuation of ADA due to adverse events were comparable in the MTX ≥10 mg and MTX <10 mg groups (11.1% vs. 12.0%). Conclusions: These findings support the critical role of concomitant MTX in the efficacy of ADA, and recommend use of MTX ≥10 mg in Japanese RA patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu